CN117159719B - Mfsd12在制备治疗肺腺癌药物中的应用 - Google Patents
Mfsd12在制备治疗肺腺癌药物中的应用 Download PDFInfo
- Publication number
- CN117159719B CN117159719B CN202311444029.4A CN202311444029A CN117159719B CN 117159719 B CN117159719 B CN 117159719B CN 202311444029 A CN202311444029 A CN 202311444029A CN 117159719 B CN117159719 B CN 117159719B
- Authority
- CN
- China
- Prior art keywords
- mfsd12
- seq
- lung adenocarcinoma
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000989639 Homo sapiens Major facilitator superfamily domain-containing protein 12 Proteins 0.000 title claims abstract description 40
- 102100029281 Major facilitator superfamily domain-containing protein 12 Human genes 0.000 title claims abstract description 39
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title claims abstract description 31
- 201000005249 lung adenocarcinoma Diseases 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000004055 small Interfering RNA Substances 0.000 claims description 22
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 19
- 230000002452 interceptive effect Effects 0.000 claims description 11
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 201000005202 lung cancer Diseases 0.000 abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 66
- 239000013598 vector Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101150085164 MFSD12 gene Proteins 0.000 description 1
- 102000015841 Major facilitator superfamily Human genes 0.000 description 1
- 108050004064 Major facilitator superfamily Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000012233 TRIzol extraction Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于肿瘤治疗技术领域,具体涉及MFSD12在制备治疗肺腺癌药物中的应用。本发明的目的是为治疗肺癌提供一种新选择。本发明的技术方案是MFSD12在制备治疗肺腺癌药物中的应用。本发明验证了MFSD12可应用于制备治疗肺腺癌的药物或抑制肺腺癌细胞增殖的产品。
Description
技术领域
本发明属于肿瘤治疗技术领域,具体涉及MFSD12在制备治疗肺腺癌药物中的应用。
背景技术
肺癌是最常见的人类恶性肿瘤之一,位居全球癌症相关死亡率之首,严重危害人类健康。非小细胞肺癌是肺癌的主要病理类型,约占肺癌确诊病例的85%,其中肺腺癌为非小细胞肺癌的主要病理类型。肺癌细胞的增殖过度及其向脑、骨、淋巴结等远处转移均是导致高死亡率及不良预后的重要原因。尽管近年来新的治疗方法不断出现,但非小细胞肺癌患者的预后仍不尽人意。从抑制肿瘤细胞增殖和转移的表型出发筛选新的抗肿瘤药物,将为肿瘤治疗提供新的方案。
主要促进因子超家族结构域12(MFSD12)是一种跨膜蛋白,属于主要的促进因子超家族(the major facilitator superfamily,MFS),具有跨生物膜转移分子的功能。它能介导半胱氨酸进入黑素体和溶酶体。有研究证实MFSD12的表达升高可以促进黑色素瘤细胞的增殖。但MFSD12在促进肺腺癌生物学行为的机制尚未见报道。
发明内容
本发明的目的是为治疗肺癌提供一种新选择。
本发明的技术方案是MFSD12在制备治疗肺腺癌药物中的应用。
本发明的另一个目的是提供了MFSD12在制备抑制肺腺癌转移药物中的应用。
本发明还提供了一种治疗肺腺癌的药物,所述药物为降低MFSD12表达的物质。
进一步,所述降低MFSD12表达的物质为干扰其表达的物质。
具体的,所述干扰其表达的物质为针对靶序列如SEQ ID No.1或/和SEQ ID No.2所示的短发夹RNA(shRNA)。
特别的,将所述shRNA构建至病毒载体中。
优选的,所述病毒载体为慢病毒载体或腺病毒载体。
进一步的,针对靶序列如SEQ ID No.1所示的shRNA的引物对如SEQ ID No.6和SEQID No.7所示。
进一步的,针对靶序列如SEQ ID No.2所示的shRNA的引物对如SEQ ID No.8和SEQID No.9所示。
本发明还提供了一种抑制肺腺癌转移的药物,所述药物为降低MFSD12表达的物质。
进一步,所述降低MFSD12表达的物质为干扰其表达的物质。
具体的,所述干扰其表达的物质为针对靶序列如SEQ ID No.1或/和SEQ ID No.2所示的shRNA。
特别的,将所述shRNA构建至病毒载体中。
优选的,所述病毒载体为慢病毒载体或腺病毒载体。
进一步的,针对靶序列如SEQ ID No.1所示的shRNA的引物对如SEQ ID No.6和SEQID No.7所示。
进一步的,针对靶序列如SEQ ID No.2所示的shRNA的引物对如SEQ ID No.8和SEQID No.9所示。
本发明还提供了检测MFSD12表达量的物质在筛选治疗肺腺癌药物中的应用。
进一步,检测MFSD12表达量的物质为扩增MFSD12的引物对。
具体的,所述扩增MFSD12的引物对如SEQ ID No.3和SEQ ID No.4所示。
本发明还提供了降低MFSD12表达的shRNA。
具体的,所述shRNA的靶序列如SEQ ID No.1或/和SEQ ID No.2所示。
进一步的,靶序列如SEQ ID No.1所示的shRNA的引物对如SEQ ID No.6和SEQ IDNo.7所示。
进一步的,靶序列如SEQ ID No.2所示的shRNA的引物对如SEQ ID No.8和SEQ IDNo.9所示。
本发明还提供了表达所述shRNA的载体或宿主细胞。
具体的,所述载体为病毒载体。
优选的,所述病毒载体为慢病毒载体或腺病毒载体。
本发明的有益效果:
本发明证明了干扰MFSD12能够抑制肺腺癌的增殖及迁移,因此在肺腺癌药物研发过程中,可作为靶点使用;也可应用于制备治疗肺腺癌的药物或抑制肺腺癌细胞增殖的产品,为肺腺癌的治疗提供了一种可能性,具有广阔的应用前景。
附图说明
图1是使用人肺腺癌细胞株构建的干扰MFSD12的稳转细胞株中的逆转录-实时荧光定量PCR(左)及蛋白印迹法(western blot)检测结果图(右)。
图2是应用细胞计数试剂盒-8(CCK-8)法检测人肺腺癌细胞株构建的干扰MFSD12的稳转细胞株中的细胞成活率统计图。
图3是应用克隆形成实验检测人肺腺癌细胞株构建的干扰MFSD12的稳转细胞株中的细胞增殖能力实验结果图;A为克隆照片图,B为克隆数统计图。
图4是应用细胞迁移实验(Tanswell实验)检测人肺腺癌细胞株构建的干扰MFSD12的稳转细胞株中的细胞迁移能力。
具体实施方式
由于目前针对MFSD12的研究,仅有文献证明了MFSD12的表达升高可以促进黑色素瘤细胞的增殖,还没有MFSD12与其他癌症相关的研究。因此,发明人基于 MFSD12序列设计了针对靶点的干扰序列,构建了慢病毒载体,转化人肺腺癌细胞H1299,获得了干扰MFSD12表达的细胞系。通过体外实验,进一步证明了干扰MFSD12表达能够显著抑制肺腺癌细胞H1299的细胞活性、增殖能力和迁徙能力。
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。
下述实施例中使用的人肺腺癌细胞H1299购于中国科学院上海生科院细胞资源中心。
实施例1 利用慢病毒MFSD12干扰载体转化人肺腺癌细胞H1299
编码MFSD12蛋白的核苷酸GeneBank登录号为NC_000019.10。利用RNA干扰(RNAi)设计软件按照 RNA 干扰序列设计原则,设计合成2条针对人MFSD12基因(GenBank:NC_000019.10)的 小干扰RNA (siRNA) 干扰靶序列和 1 条阴性对照序列,2 条 siRNA 序 列分 别 为: MFSD12-RNAi-1 ∶ 5 ’- GCATACTGTACATGACCACCA-3’ (SEQ ID NO.1);MFSD12-RNAi-2 ∶ 5’- GCCCATCAACAAGTGCATTGG-3’ (SEQ ID NO.2)。 阴性对照序列:5’-TTCTCCGAACGTGTCACGT-3’ (SEQ ID NO.5)。 在上述序列两端加上酶切位点,中间插入Loop环,设计shRNA片段。
MFSD12-shRNA1-F(SEQ ID NO.6):Ccgg(酶切位点)GCATACTGTACATGACCACCACTCGAG(LOOP环)TGGTGGTCATGTACAGTATGCTTTTTg(酶切位点);
MFSD12-shRNA1-R(SEQ ID NO.7):aattcaaaaa(酶切位点)GCATACTGTACATGACCACCACTCGAG(LOOP环)TGGTGGTCATGTACAGTATGC。
MFSD12-shRNA2-F(SEQ ID NO.8):Ccgg(酶切位点)GCCCATCAACAAGTGCATTGGCTCGAG(LOOP环)CCAATGCACTTGTTGATGGGCTTTTTg(酶切位点);
MFSD12-shRNA2-R(SEQ ID NO.9):aattcaaaaa(酶切位点)GCCCATCAACAAGTGCATTGG(LOOP环)TGGTGGTCATGTACAGTATGC。
阴性对照-F(SEQ ID NO.10):Ccgg(酶切位点)TTCTCCGAACGTGTCACGTTTCAAGAGA(LOOP环)ACGTGACACGTTCGGAGAATTTTTg(酶切位点);
阴性对照-R(SEQ ID NO.11):aattcaaaaa(酶切位点)TTCTCCGAACGTGTCACGTTTCAAGAGA(LOOP环)ACGTGACACGTTCGGAGAA。
序列合成、慢病毒载体的构建及包装由上海吉凯基因技术有限公司完成。H1299细胞使用RPMI-1640完全培养基培养(含10%胎牛血清、1%青链霉素双抗),培养箱条件为37℃、5%CO2。当细胞汇合度达到90%左右并处于对数生长期时,消化并重悬H1299细胞接种于6孔板中,将上述阴性对照(NC)及MFSD12的干扰慢病毒按说明书进行转染,分为NC及shRNA1、shRNA2组,72h后通过荧光显微镜观察荧光,观察结果显示细胞感染效率达到80%以上,可用于后续实验。
(2)收集(1)中各组细胞并提取RNA,所用试剂盒为Trizol提取试剂盒(invitrogen公司)。先去除基因组DNA,再进行逆转录合成cDNA产物;以cDNA产物为模板,应用本发明试剂盒所包含的引物对进行荧光定量PCR,所用试剂盒为SYBRGreen PCR试剂盒(Thermo公司),PCR仪器为ABI公司荧光定量PCR仪器。选取人内源性肌动蛋白基因表达水平为内参,mRNA相对表达水平的计算公式为2-ΔΔCT。
其中,MFSD12引物对的核苷酸序列如下:
上游引物:5’ gcttcttgtcctccttcctcat 3’ (SEQ ID NO.3);
下游引物:5’ cacgaacgctccgctgtt 3’ (SEQ ID NO.4)。
人内源性肌动蛋白基因表达水平为内参,引物对的核苷酸序列如下:
上游引物:5’ gcgtgacattaaggagaagc 3’ (SEQ ID NO.12);
下游引物:5’ ccacgtcacacttcatgatgg 3’ (SEQ ID NO.13)。
逆转录-实时荧光定量(Real time-PCR)反应体系,根据Real time-PCR反应体系配制反应液。在PCR反应管中分别加入ddH2O、SybrGreen qPCR Master Mix(SybrGreenqPCR 预混物)、上游引物、下游引物和cDNA模板,充分混匀。扩增条件:94℃ 10 min,(94℃20秒, 55℃ 20秒, 72℃ 20秒) 40个循环。上述试剂均来自逆转录试剂盒(Thermo公司)与SYBRGreen PCR试剂盒(Thermo公司)。
(3)取(1)中的各组细胞,使用蛋白裂解液(2×loading buffer)裂解细胞提取蛋白,并在95℃条件下金属浴10min使蛋白边变性。吸取8μL样品加入 上样孔中,使用140V电泳60min,200mA转膜90min,5%脱脂牛奶进行封闭。1h后等渗缓冲盐溶液(TBST)清洗聚偏二氟乙烯膜 (PVDF)膜3次,将PVDF膜与一抗(抗人 MFSD12多克隆抗体1︰1000、抗人肌动蛋白单克隆抗体1︰8000)室温孵育2h。TBST将PVDF膜清洗3次后放于辣根过氧化物酶(HRP)标记的抗兔 IgG二抗(1︰5000)中孵育1h。TBST清洗后使用超敏发光液进行显影。
结果如图1所示使用H1299细胞MFSD12基因稳转干扰细胞株构建成功,使用PCR及蛋白印迹(Western blot)实验检验MFSD12干扰效果。相比对照组,敲低组中MFSD12的mRNA及蛋白质表达水平均显著下调。同时将构建成功的细胞株冻存于-80℃。
实施例2敲低MFSD12 的表达对H1299细胞活性及增殖能力的影响
应用细胞计数试剂盒-8(CCK-8)实验及细胞克隆形成实验检测,具体实施过程如下:
(1)收集实施例1中的各组细胞,将处于对数生长期的各实验组细胞胰酶消化 后,完全培养基重悬成细胞悬液,并计数。铺板细胞密度为2000/孔,每孔100 μL,每组3孔重复,铺5张96孔板。统一铺好后,待细胞完全沉淀下来后,在显微镜下观察各实验组的细胞密度,如果密度不均匀,则固定一组,微调其他组细胞的量再次铺板(如:发现对照组细胞较多,降低细胞量再次铺板),放入细胞培养箱中培养。从铺板后第二天开始,培养终止前2~4h加入10μL CCK8试剂于孔中,无需换液,连续检测5天。2~4 h后96孔板置于振荡器上振荡2~5min,酶标仪450 nm检测OD值。数据统计分析。
由图2可知,干扰MFSD12表达能够显著抑制肺腺癌细胞H1299的细胞活性。
(2)于6孔板培养板中各实验组接种细胞,铺板量为1000/孔。将接种好的细胞于培养箱中继续培养,至对照组绝大多数单个克隆中细胞数大于50为止,中途需要对细胞每2~3天进行换液并观察细胞状态。培养7天后于显微镜下对细胞克隆进行拍照,磷酸盐生理平衡盐水(PBS)洗涤细胞1次。每孔加入1 mL 4%多聚甲醛,固定细胞30~60 min,PBS洗涤细胞1次。每孔加入结晶紫染液1000 μL,染细胞10~20 min。ddH2O洗涤细胞数次,晾干,将整个培养板拍照,克隆计数。结果分析。
由图3可知,干扰MFSD12表达的H1299稳转细胞株克隆显著减少,说明MFSD12可调控肺腺癌细胞的增殖。
实施例3干扰MFSD12表达对H1299细胞迁移能力的影响
应用细胞迁移实验(Transwell实验)检测,具体过程如下:
取出Transwell试剂盒,将所需数目的小室置于新的24孔板中,上室加100 µL无血清培养基,37℃培养箱中放置1 h。H1299各实验组细胞接种于Transwell小室中,为50000/孔(24孔板)。小心除去上室中培养基并加入100 µL细胞悬液,下室内加入600 µL 30%胎牛血清 (FBS)培养基。37℃培养箱培养16h后倒扣小室于吸水纸上以去除培养基,用棉拭子轻轻移去小室内非转移细胞,将小室置于4%多聚甲醛固定液中固定半小时。固定后,将小室捞出,用吸水纸吸干小室表面固定液,滴1~2滴染色液到膜的下表面染色转移细胞1~3 min后,将小室浸泡冲洗数次,空气晾干。显微镜拍照:每个Transwell小室,随机选取视野,200×照片9张。以200×的照片来计数,进行数据分析,比较实验组与对照组细胞转移能力的差异:计算各组转移细胞数。
由图4可知,干扰MFSD12表达能够显著抑制H1299细胞的迁移。
以上所述实施例仅为本发明优选的具体实施方案,并不用来限制本发明,凡是在本发明精神和原则之内,所作的任何修改、等同替换以及改进等,均应包含在本发明的保护范围之内。
Claims (1)
1.干扰MFSD12 表达的shRNA在制备治疗肺腺癌药物或抑制肺腺癌转移药物中的应用,其特征在于: shRNA的靶序列如SEQ ID No.1 或/和SEQ ID No.2 所示;针对靶序列如SEQID No.1 所示的shRNA 的引物对如SEQ ID No.6 和SEQ ID No.7 所示;针对靶序列如SEQID No.2 所示的shRNA 的引物对如SEQ ID No.8 和SEQ ID No.9 所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311444029.4A CN117159719B (zh) | 2023-11-02 | 2023-11-02 | Mfsd12在制备治疗肺腺癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311444029.4A CN117159719B (zh) | 2023-11-02 | 2023-11-02 | Mfsd12在制备治疗肺腺癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117159719A CN117159719A (zh) | 2023-12-05 |
CN117159719B true CN117159719B (zh) | 2024-01-30 |
Family
ID=88930089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311444029.4A Active CN117159719B (zh) | 2023-11-02 | 2023-11-02 | Mfsd12在制备治疗肺腺癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117159719B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10345302B2 (en) * | 2017-02-19 | 2019-07-09 | Sheng-He Huang | Circulating astrocytes and MFSD2A as biomarkers |
-
2023
- 2023-11-02 CN CN202311444029.4A patent/CN117159719B/zh active Active
Non-Patent Citations (3)
Title |
---|
Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma;Chuan-Yuan Wei等;《Oncogene》;第1876-1891页及Electronic supplementary material * |
Chuan-Yuan Wei等.Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.《Oncogene》.2018,第1876-1891页及Electronic supplementary material. * |
Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non–Small Cell Lung Carcinoma;Xiang Zheng等;《Cancer research》;第4414-4425页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117159719A (zh) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility | |
Li et al. | MiR-155 up-regulated by TGF-β promotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells in vitro | |
Yang et al. | CircRNA_100876 promote proliferation and metastasis of breast cancer cells through adsorbing microRNA-361-3p in a sponge form. | |
Sekine et al. | S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells | |
Wang et al. | Fibulin-4 is associated with prognosis of endometrial cancer patients and inhibits cancer cell invasion and metastasis via Wnt/β-catenin signaling pathway | |
Guo et al. | Influences of LncRNA SNHG20 on proliferation and apoptosis of glioma cells through regulating the PTEN/PI3K/AKT signaling pathway. | |
Zhang et al. | MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4. | |
Li et al. | Long non-coding RNA LINC00847 induced by E2F1 accelerates non-small cell lung cancer progression through targeting miR-147a/IFITM1 axis | |
Xuan et al. | miR‑218 suppresses the proliferation of osteosarcoma through downregulation of E2F2 | |
CN109055374B (zh) | 特异性抑制OCT1基因表达的shRNA及应用 | |
Zeng et al. | Hsa_circRNA_100146 promotes prostate cancer progression by upregulating TRIP13 via sponging miR-615-5p | |
Li et al. | Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis | |
CN111378753A (zh) | 人pno1基因在肺癌中的用途及相关产品 | |
Xue et al. | LncRNA loc339803 acts as CeRNA of miR-30a-5p to promote the migration and invasion of hepatocellular carcinoma cells | |
Cui et al. | DGCR8 promotes the metastasis in triple-negative breast cancer by epigenetically regulating TGF-β. | |
Wang et al. | Low Levels of SPARC are associated with tumor progression and poor prognosis in human endometrial carcinoma | |
Wang et al. | Inhibition of prostate cancer DU145 cell growth with small interfering RNA targeting the SATB1 gene | |
CN109321655A (zh) | Nkiras2基因调控区序列、调控序列及其在鼻咽癌中的应用 | |
CN117159719B (zh) | Mfsd12在制备治疗肺腺癌药物中的应用 | |
CN108165631B (zh) | 一种骨肉瘤的生物标志物syt12及其应用 | |
Zhang et al. | Long noncoding RNA TFAP2A-AS1 exerts promotive effects in non-small cell lung cancer progression via controlling the microRNA-548a-3p/CDK4 axis as a competitive endogenous RNA | |
CN114075562A (zh) | Mage-c3抑制剂及其作为制备治疗和/或预防食管鳞状细胞癌药物的用途 | |
CN112826826B (zh) | 一种siRNA序列在制备治疗卵巢癌药物中的应用 | |
Liu et al. | RNAi-mediated downregulation of DNA binding protein A inhibits tumorigenesis in colorectal cancer | |
CN111705060B (zh) | 一种NCAPD2基因的shRNA及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |